#United States #San Francisco #GeneDx #Fabric Genomics #NASDAQ WGS

GeneDx Holdings Under Fire Following Stock Plunge

GeneDx Holdings Inc., listed on NASDAQ as WGS, has recently been embroiled in controversy following a catastrophic earnings report that resulted in a staggering 49% decline in stock value. On May 5, 2026, the company’s shares plummeted by $33.42, raising alarm bells among investors and prompting a securities class action lawsuit.

The Class Action Lawsuit

The lawsuit targets individuals who acquired shares between April 16, 2025, and May 4, 2026. Hagens Berman, a national shareholder rights law firm, is investigating allegations that GeneDx made misleading claims concerning its business practices and financial expectations. Losses incurred by investors have driven the firm to urge those affected to step forward and explore their legal rights.

Historically, GeneDx has been a player in clinical diagnostics, focused on testing for rare diseases through whole genome and exome sequencing. With a business model reliant on genomic testing, the company had previously boasted about its consistent revenue growth, particularly emphasizing its average reimbursement rate (ARR) of $3750 in 2025.

The Acquisition and Subsequent Downfall

GeneDx's acquisition of Fabric Genomics for approximately $33.2 million in May 2025 was touted as a strategic move aimed at diversifying its revenue streams and enhancing its operational offerings. However, the acquisition has since been called into question, particularly regarding its financial impact. The company recorded significant impairment charges amounting to $31.2 million related to the Fabric acquisition – a staggering write-off of about 94% of the investment made just a year prior.

The complaints allege that GeneDx not only misled its investors about the value and impact of Fabric Genomics but also failed to disclose the declining margins that were affecting its expected financial performance.

On May 4, 2026, the first quarter earnings report reflected a tenfold increase in net losses compared to the same period in the previous year, revoking the company’s earlier optimistic projections and leading to a revised revenue guidance cut by 12% for the remaining year.

Financial Transparency Issues

The company’s narrative of growth shattered when their first quarter results revealed declining revenues in both genomic and exomic tests, a stark contradiction to earlier forecasts of 33% to 35% revenue growth. Moreover, the decline in ARR, reduced by around $200, highlighted a concerning shift in the product mix that favored genomic tests with lower reimbursement rates.

“What has become evident is that GeneDx may have intentionally misled investors about the ramifications of their acquisition and the real value it would provide,” stated Reed Kathrein, the lead partner investigating the case. The situation is compounded by rapidly shifting product dynamics that further adjusted profitability strategies and future growth potential.

Looking Ahead

The securities class action lawsuit presents a growing challenge for GeneDx as it attempts to recover stakeholder trust amid turbulent financial prospects. The ongoing investigation is poised to delve further into the company's management decisions, with particular focus on when the executive team became aware of the adverse product mix changes.

In light of these events, investors are being encouraged to submit any relevant information or experiences they might have had in relation to GeneDx to assist in the investigation. The firm is also pointing to a whistleblower program that could provide rewards for individuals who share critical information.

As the situation unfolds, GeneDx Holdings’ future remains uncertain while investors grapple with the repercussions of a rapidly deteriorating financial landscape and potential corporate malpractice.